Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective
2019 ◽
Vol 25
(1)
◽
pp. 94-101
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2018 ◽
Vol 21
(8)
◽
pp. 770-777
◽
Keyword(s):
Keyword(s):
2010 ◽
Vol 13
(8)
◽
pp. 893-902
◽
Keyword(s):